Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Completed · Phase 1

Conditions studied: Respiratory Syncytial Virus Infections

In brief

This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.

Key facts

Study ID

NCT04227210

Run by

Meissa Vaccines, Inc.

People needed

20

Starts

2020-01-14

Expected to finish

2020-08-27

Last updated by the study team

2020-09-16

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• Occupational or household exposure to children < 5 years of age, or to immunocompromised individuals
• Prior receipt of an investigational RSV vaccine
• Women who are pregnant, lactating, or unwilling to take effective measures to prevent pregnancy for at least 3 months after vaccination
• Any other reason the Investigator considers exclusionary

Where it is running

• Johnson County Clin-Trials — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.